NBNikita V. Baclig

Nikita V. Baclig

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Nikita V. Baclig has a total of 51 co-authors. Here are the top co-authors by number of shared publications:

  • Antonia Osuna-Garcia

    UCLA Louise M. Darling Biomedical Library, Los Angeles, USA

    2 shared publications
  • Eden R. Brauer

    UCLA School of Nursing, Los Angeles, USA

    2 shared publications
  • Patricia A. Ganz

    UCLA Fielding School of Public Health, David Geffen School of Medicine at UCLA, Los Angeles, USA

    2 shared publications
  • Vivek Chotai

    University of California Los Angeles, Los Angeles, USA

    2 shared publications
  • Aileen T. MacAndrew

    Division of Hematology and Oncology, Department of Medicine, David Geffen School of Medicine at University of California Los Angeles, Los Angeles, California

    1 shared publication
  • Alexis LeVee

    1 shared publication

Latest Publications

  • Open Access

    Early discontinuation of chemotherapy in older adults with early breast cancer: results from the prospective multicenter HOPE study

    by Jingran Ji, Can-Lan Sun, William Dale, Harvey Jay Cohen, Heeyoung Kim, Vani Katheria, Nikita Baclig, Yuliya Zektser, Arman Niknafs, Samuel Margolis, et al.

    Purpose: Older adults with early-stage breast cancer (EBC) receiving neo/adjuvant chemotherapy frequently discontinue treatment early. However, the incidence, risk factors, and survival implications of early discontinuation remain poorly understood. Methods: This is a post hoc analysis of 501 older adults (aged ≥65) with EBC treated with neo/adjuvant chemotherapy from the Hurria Older PatiEnts (HOPE) Study. Before chemotherapy, we collected sociodemographic, clinical, and geriatric assessment characteristics. The primary outcome was early discontinuation (yes/no), defined as not completing all planned chemotherapy. We used multivariable logistic regression with stepwise selection to identify pretreatment risk factors and the Kaplan-Meier method to evaluate the impact of discontinuation on survival. Results: Of 501 participants (median [range] age, 70 [65-86] years), 113 (23%) had early discontinuation. After multivariable analysis, ≥1 fall within 6 months (odds ratio [OR] = 2.06, 95% CI = 1.11 to 3.81, P = .02) and an activity of daily living score <85 (OR = 2.00, 95% CI = 1.26 to 3.18, P = .003) were identified as risk factors for early discontinuation. Participants with both risk factors were at highest risk (OR = 4.61, 95% CI = 2.18 to 9.79, P < .001). With a median follow-up of 4.3 years, early discontinuation was not associated with worse overall or breast cancer-specific survival but was associated with higher non-breast cancer-specific mortality (hazard ratio = 2.94, 95% CI = 1.22 to 7.07, P = .02). Conclusion: In this cohort of older adults with EBC, nearly one-quarter discontinued chemotherapy early. Early discontinuation was associated with increased non-cancer-related mortality but not cancer-related mortality, emphasizing the importance of identifying high-risk older adults and optimizing treatment delivery.


  • Open Access

    Incidence, Risk Factors, and Survival Implications of Immune-Related Adverse Events in Patients With Metastatic Breast Cancer

    by Nikita V. Baclig, Madhuri Chengappa, Andrew J. Soliman, Saya Jacob, Alexis LeVee, Samantha Fisch, Carolyne Face, Saliha Chaudhry, Dame Idossa, Thejaswi Poonacha, et al.


  • Open Access

    Oncofertility patterns after the overturn of Roe v Wade

    by Nikita V Baclig, Jordyn Silverstein, Vrushangi Shah, Beth Karlan, Sidharth R Anand, John A Glaspy

    The 2022 US Supreme Court decision Dobbs v Jackson Women’s Health Organization raised concerns about access to fertility care for patients with cancer, yet there is limited evidence of its real-world impact. We conducted a national survey of National Comprehensive Cancer Network member institutions to evaluate changes in fertility preservation access and utilization in the 24 months following Dobbs. Of 33 institutions surveyed, 24 (72.7%) responded. Most (83.3%) institutions reported that reproductive care remained a clinical priority, and 62.5% reported increased fertility preservation utilization. Nearly all respondents reported stable or expanded institutional resources and staffing to support oncofertility services. Institutions in less restrictive states appeared to absorb increased demand, however notable nonresponse from institutions in restrictive policy environments limited our findings. This study suggests relative resilience among academic cancer centers but highlights the need for further study to ensure equitable access to fertility preservation in the post-Dobbs era.

  • Colorectal Cancer Arising in a Colon Interposition After Esophageal Reconstruction: The Medical Oncology Perspective

    by Nikita V. Baclig, Aileen T. MacAndrew, Jane Yanagawa, Alireza Sedarat, Bernard J. Katz, David W. Dawson, Mark D. Girgis, Lee S. Rosen

  • Open Access

    The sequelae of hematopoietic stem cell transplantation in adolescents and young adults: protocol for a systematic review

    by Nikita V. Baclig, Antonia Osuna-Garcia, Vivek Chotai, Patricia A. Ganz, Eden R. Brauer

    Background: Hematopoietic stem cell transplantation (HSCT) is a life-saving treatment for adolescents and young adults (ages 15–39) with hematologic malignancy. Given the significant developmental milestones usually achieved during this unique life stage, this population is especially vulnerable to the interruption caused by a cancer diagnosis and its treatment. HSCT is a particularly invasive form of cancer therapy with many negative physical, social, and psychological sequelae. The long-term impact of HSCT in adolescents and young adults with hematologic malignancies warrants a systematic investigation of its effects to best shape clinical care and health policy. Methods: This protocol for a systematic review will focus on the long-term physical, psychological, social, spiritual, and health behavior effects experienced by adolescents and young adults who undergo HSCT for hematologic malignancy. We have constructed a specific search strategy that queries these five domains, which will be applied to five databases—Embase, PubMed, Cochrane Trials and Reviews, PsychInfo, and CINAHL—to identify the key literature. Two independent reviewers will perform a title/abstract screen followed by a full-text screen using standard screening templates to ensure the inclusion of outcomes in the post-acute HSCT period. Risk of bias will be assessed using the University of Adelaide Joanna Briggs Institute Collaboration Critical Appraisal Tools. Data from included studies will be abstracted on study characteristics, study setting, sample characteristics, and outcomes. Given the broad scope of the research question, data synthesis will focus on qualitative methods in accordance with Institute of Medicine standards. Discussion: While adolescents and young adults undergoing hematopoietic stem cell transplantation for hematologic malignancy are understood to have a unique survivorship experience, the sequelae of this treatment approach in this population have not been previously aggregated. This systematic review intends to expand insight into the adolescent and young adult experiences with HSCT in order to inform age-appropriate survivorship care and deliver this life-saving intervention with the best possible outcomes. Systematic review registration: PROSPERO CRD42022361663


  • Open Access

    Mental health and care utilization in survivors of adolescent and young adult cancer

    by Nikita V Baclig, Warren Scott Comulada, Patricia A Ganz

    Adolescent and young adult cancer survivors experience mental health challenges, yet little is known about the evolution of these difficulties. This study explored mental health symptoms and utilization among long-term adolescent and young adult cancer survivors. Using 30 432 respondents from the 2019 National Health Interview Survey, this study compared adults with a history of adolescent and young adult cancer (diagnosed when patients were between 15 and 39 years of age) to adults without adolescent and young adult cancer. Mental health symptom severity was measured using the Patient Health Questionnaire depression scale and 7-item Generalized Anxiety Disorder questionnaires. Care utilization constituted psychotherapy and mental health medication use. Inverse propensity score weights were used to balance demographics and combined with survey weights. Descriptive statistics, multivariable generalized linear models, and structural equation modeling with 2-sided tests were used for analysis. We compared 639 adolescent and young adult survivors with 29 793 controls. Survivors were, on average, 20.5 years (SE = 0.74) past their cancer diagnosis dates. After adjusting for survey and propensity score weights, adolescent and young adult survivors reported more severe depression (incidence rate ratio = 1.42, 95% confidence interval [CI] = 1.09 to 1.84, P < .01) and anxiety (incidence rate ratio = 1.85, 95% CI = 1.55 to 2.21, P < .001). They were more likely to use psychotherapy (odds ratio = 1.91, 95% CI = 1.16 to 3.17, P < .05) and mental health medications (odds ratio = 1.89, 95% CI = 1.15 to 3.11, P < .05). Time since diagnosis was negatively associated with symptoms and utilization. Structural equation modeling demonstrated mediation of utilization effect by symptom severity. Adolescent and young adult survivors experience worse mental health in late survivorship, despite small improvements over time. We highlight the importance of survivorship care that addresses the long-term mental health needs of these survivors.


  • Open Access

    The Sequelae of Hematopoietic Stem Cell Transplantation in Adolescent and Young Adults: Protocol for A Systematic Review

    by Nikita V Baclig, Antonia Osuna-Garcia, Vivek Chotai, Patricia A. Ganz, Eden R. Brauer

    Background Hematopoietic stem cell transplantation (HSCT) is a life-saving treatment for Adolescent and Young Adults (age 15–39) with hematologic malignancy. Given the significant developmental milestones usually achieved during this unique life stage, this population is especially vulnerable to the interruption caused by a cancer diagnosis and its treatment. HSCT is a particularly invasive form of cancer therapy with many negative physical, social, and psychological sequelae. The long-term impact of HSCT in Adolescent and Young Adults with hematologic malignancies warrants a systematic investigation of its effects to best shape clinical care and health policy. Methods This protocol for a systematic review will focus on the long-term physical, psychological, social, spiritual, and health behavior effects experienced by Adolescents and Young Adults who undergo HSCT for hematologic malignancy. We have constructed a specific search strategy that queries these 5 domains, which will be applied to five databases – Embase, Pubmed, Cochrane Trials and Reviews, PsychInfo, and CINAHL – to identify key literature. Two independent reviewers will perform a title/abstract screen followed by full-text screen using standard screening templates to ensure inclusion of outcomes in the post-acute HSCT period. Risk of bias will be assessed using the University of Adelaide Joanna Briggs Institute Collaboration Critical Appraisal Tools. Data from included studies will be abstracted on study characteristics, study setting, sample characteristics, and outcomes. Given broad scope of the research question, data synthesis will focus on qualitative methods in accordance with Institute of Medicine standards. Discussion While Adolescent and Young Adults undergoing Hematopoietic Stem Cell Transplantation for hematologic malignancy are understood to have a unique survivorship experience, the sequelae of this treatment approach in this population have not been previously aggregated. This systematic review intends to expand insight into the Adolescent and Young Adult experiences with HSCT in order to inform age-appropriate survivorship care and deliver this life-saving intervention with the best possible outcomes. Systematic Review Registration PROSPERO registration number: CRD42022361663.